Research
Hormonal
GLP-1 receptor agonists (specifically high-dose liraglutide 3.0 mg) produce clinically significant weight loss (5.9 kg/year) by enhancing satiety via hypothalamic stimulation and delaying gastric emptying.
If you have obesity (BMI ≥ 30, or ≥ 27 with health issues), a daily 3.0 mg injection of liraglutide can help you lose 5-6 kg per year by making you feel full faster and keeping you full longer. You must manage potential nausea, which is common, and this is prescribed for long-term use, not just a quick fix.
GoodSupportsHIGH confidence
Liraglutide improves weight loss by enhancing satiety via hypothalamic stimulation and delaying gastric emptying, thereby reducing food intake... An additional annual weight loss of 5.3–5.9 kg has been observed compared with placebo
Why this rating
Based on FDA/EMA approval and multiple systematic reviews/meta-analyses cited, though side effects are noted.
Source
Drug Therapy in Obesity: A Review of Current and Emerging Treatments
David M. Williams et al. · Diabetes Therapy · 2020
DOI 10.1007/s13300-020-00816-y
narrative_reviewCited 196×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- SGLT-2 inhibitors produce modest weight loss (2.1-2.7 kg) in people with Type 2 Diabetes by inducing glucose-mediated osmotic diuresis, but are not yet approved specifically for obesity treatment.Good
- Multi-agonists (GLP-1/Glucagon, GLP-1/GIP, or GLP-1/GIP/Glucagon) show greater potential for weight loss than single-agonists by combining appetite suppression with increased energy expenditure.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →